Cipla may face a significant setback to its US growth trajectory after a regulatory action impacted supplies of a key product, with brokerage firm Macquarie flagging a potential revenue risk of up to $100 million.
According to Macquarie, the US Food and Drug Administration (USFDA) has placed an import alert on Pharmathen’s Greece-based manufacturing facility, which supplies Lanreotide — a key injectable drug used in the treatment of certain hormonal disorders — to the US market. The development effectively blocks shipments from the facility, disrupting supply chains for the product.
The brokerage estimates that Cipla could see $90–100 million in revenues at risk due to the disruption. It noted that earlier expectations of a restart in supplies by FY27 now appear unlikely, indicating a longer-than-anticipated impact.
Macquarie further cautioned that even FY28 contribution from the product could remain weak, signalling a prolonged drag on Cipla’s US business outlook. “Net: clear setback to Cipla’s US growth outlook,” the brokerage said in its note.
The development adds to concerns around Cipla’s dependence on external manufacturing partners for certain specialty products in regulated markets like the US. Lanreotide has been seen as an important contributor to Cipla’s specialty portfolio, particularly in the high-margin US generics segment.
As reported earlier, the USFDA’s import alert on the partner facility has raised uncertainty around the continuity of supplies, which could impact near- to medium-term earnings visibility. The situation may also delay Cipla’s ability to scale up its presence in niche therapies where regulatory compliance and uninterrupted supply are critical.
The US market remains a key growth driver for Cipla, and any disruption in product availability — especially in limited-competition segments — can have a meaningful impact on overall performance.
Going ahead, investors are likely to closely monitor regulatory developments, potential remediation timelines at the Pharmathen facility, and Cipla’s contingency plans to mitigate the supply disruption.
Disclaimer: This article is based on brokerage commentary and publicly available information. The views expressed are those of the brokerage and do not constitute investment advice.